Charles et al. has also reported that polymorphism of CYP3A5 were accompanied with a higher risk of diarrhea in erlotinib treated NSCLC patients (Rudin et al., 2008). This evidence concerns the gene CYP3A5 and non-small cell lung carcinoma.